|
|
303-A College Road East
Princeton, NJ 08540 USA
phone:(609) 613-4100
fax:(609) 613-4150 |
| Symbol |
VRUS |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
|
|
|
| www.pharmasset.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Therapeutics for infections caused by human immunodeficiency virus and hepatitis viruses. |
|
| Management |
| P. Schaefer Price, M.B.A., Chief Executive Officer And Director; Kurt Leutzinger, C.P.A., M.B.A., Chief Financial Officer; M. Michelle Berrey, M.D., M.P.H, Chief Medical Officer; Michael J. Otto, Ph.D. Chief Scientific Officer; Michael D. Rogers, Ph.D., Chief Development Officer |
|
|
|
|
| Keywords |
| infection, HIV, hepatitis, drug-resistant, clevudine, dexelvucitabine |
|
|
|
|
| Description |
|
Pharmasset, Inc. specializes in nucleoside chemistry to develop therapeutics to combat infections caused by drug-resistant human immunodeficiency virus (HIV) and hepatitis viruses. |
|
| Products / Services |
Pharmasset's product candidates include: Clevudine, which is in late-stage clinical trials for the treatment of chronic Hepatitis B;
Dexelvucitabine and Racivir, two drugs in Phase 2 clinical trials for the treatment of HIV; PSI-6130 for the treatment of Hepatitis C.
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
